CClinicalTrials.gg
Status unknownNCT02903719Updated Sep 23, 2016

The Effect of Phrenic Nerve Block on Postoperative Shoulder Pain in Patients for Liver Resection.

A Phase 4 interventional study of Ropivacaine in Shoulder Pain, Surgery and Nerve Block, sponsored by Eske Kvanner Aasvang. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Eske Kvanner Aasvang · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to explore whether the use of ultrasound guided phrenic nerve block can reduce the postoperative pain in the shoulder after liver resection. The intervention is directed postoperative to the patients experiencing novel right sided shoulder pain.

Read the detailed description

Background:

Patients undergoing both laparoscopic and open hepatic surgery often experience shoulder pain in the postoperative period, mostly on the right side.

The mechanism behind referral of pain from surgical sites to the ipsilateral (same side) shoulder is not fully understood. It has been stated, that the sharing of cervical sensory roots, leads the brain to an interpretation that the pain as originating from the ipsilateral shoulder, when the phrenic nerve is stimulated.

The phrenic nerve provides both sensory and motor nerves to the diaphragm, and sensory fibers to parts of the pleura and peritoneum. Furthermore, one anatomical study indicate, that the phrenic nerve on the right side supply the liver capsule with thin sensory nerves. This could also, in part, explain the shoulder pain after liver surgery.

Studies assessing the effect of phrenic block on shoulder pain by surgically applied intrathoracic block of the phrenic nerve, have found a pain reduction, without significant side effects. There are no available studies on the effect of phrenic nerve block after hepatic surgery. Blocking the nerve intraoperatively, as described in thoracic surgery, is not possible during these operations.

Pilot study of the incidence: A recent survey at Rigshospitalet, Denmark, revealed, that 19 out of 60 patients undergoing various types of hepatic surgery, experienced moderate to severe right sided shoulder pain in the post operative care unit. The only semi-effective treatment, has been opioids (morphine), often leading to significant side effects (nausea, vomiting , dizziness) with a potential for an increase in postoperative morbidity. Furthermore, referred shoulder pain affects the respiratory capacity postoperatively.

The investigators have developed a method for applying ultrasound-guided block at the lateral side of the neck, directly at the phrenic nerve where it crosses over the scaleni anterior muscle. The block is done with low volume of local anesthetic (only 3 ml very close to the nerve) aiming to avoid affection of the brachial plexus.

The phrenic nerve block have been performed at right sided shoulder pain in the postoperative care unit with marked effect within a few minutes (small nerve with little perineural insulation).

Trial endpoints:

The idea of the study is to perform a precise, low volume, ultrasound guided nerve block in the patients who experience a severe right sided shoulder pain (NRS >5 on a 0-10 scale) after liver surgery and evaluate the effect of active substance vs. placebo

Furthermore the investigators wish to stablish an evaluation of the duration of the phrenic nerve block when it comes to pain intensity, incidence of referred shoulder pain after liver surgery, and need for opioid and to evaluate the effect of the block on the lung function.

The study results will be described in a primary publication regarding the primary outcome, and a secondary publication regarding the incidence of acute respiratory and ventilatory affection observed in the PACU in patients undergoing open liver resection.

02

Conditions studied

  • Shoulder Pain
  • Surgery
  • Nerve Block

Browse trials for

Keywords

  • Phrenic
  • Nerve block
  • Postoperative shoulder pain
  • Liver resection
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age above 18.
  • Patients scheduled for liver resection.
  • Ability to give informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial, dealing with pain or management of pain, which could affect this trial, evaluated by the investigator.
  • Inability to talk and understand danish
  • Drug or alcohol abuse
  • Pregnancy
  • Congestive heart failure (NYHA class III-IV), or other serious heart disease.
  • Chronic obstructive lung disease, moderate or severe degree, or other significant lung disease
  • Chronic or acute shoulder pain prior to surgery.
  • Body Mass Index above 35.
  • Infection at the site of the injection
  • Allergy to ropivacaine

Postoperative:

  • Shoulder pain score \< 6 assessed on the numeric rating scale (0-10), 15 minutes after arrival in postanaesthetic care unit (PA CU).
  • Insufficient epidural analgesia, or lack of epidural analgesia.
  • Inability to visualize nervus phrenicus with sonography.
  • Cerebral confusion, postoperative delirium or other medical condition hindering study intervention.
  • Presence of an investigator with intervention competence is not available.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Group A

    1. st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml 2. nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml

    Drug: Ropivacaine

  • Other
    Group B

    1. st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml 2. nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml

    Drug: Ropivacaine

Interventions

  • DrugRopivacaine

    All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.

    Also known as: Naropin

05

What researchers measure

Primary outcomes

  1. Pain measurements on a NRS (Numeric Rating Scale)

    Patients are asked to rate the intensity of their shoulder pain (if any) according to NRS (Numeric Rating Scale) from 0-10 (0=no pain, 10=the worst pain imaginable). For patients receiving the intervention they are asked to rate the intensity of their pain 15 minutes after the 1st intervention.

    Time frame: 1 hour

Secondary outcomes

  1. Lung function assessed by Spirometry

    Lung function evaluated with spirometry (FEV1, FVC og VC) just prior to 1st intervention (baseline), compared to lung function after 1st intervention or 2nd intervention. Patients receiving the interventions get their lung function measured 3 times after the interventions. Patients excluded postoperatively get their lung function measured once.

    Time frame: 1 day

  2. Lung function assessed by arterial blood gas

    Lung function evaluated with arterial blood gas (paO2, paCO2) just prior to 1st intervention (baseline), compared to lung function after 1st intervention or 2nd intervention. Lung function is also evaluated with arterial blood gas one hour after 2nd intervention.

    Time frame: 1 hour

  3. Duration of surgery compared to shoulder pain

    Duration of surgery compared to shoulder pain just prior to 1st intervention. The intensity of pain is measured according to NRS (0-10, 0=no pain, 10=worst pain imaginable).

    Time frame: 1 hour

  4. Number of included patients with low pain score (NRS) after interventions.

    Number of included patients with a pain score (NRS) between 0 and 3 after 1st intervention or 2nd intervention.

    Time frame: 1 hour and 15 minutes

  5. Number of patients with respiratory affection

    Number of included patients with respiratory affection, if defined as this in the medical chart.

    Time frame: 1 day

  6. Number os patients treated with opioid

    Number of included patients treated with opioid and the amount of used opioid in morphine equivalence.

    Time frame: 2 hours

  7. Prevalence of respiratory and cardiovascular events amon included and excluded patients.

    Prevalence of respiratory og cardiovascular events until discharge when defined as this in medical chart and prevalence of readmission obtained from the Danish National Hospital Registry.

    Time frame: 30 days

  8. Pain measurements 24 hours after the 1st intervention.

    Patients are asked to rate the intensity of their shoulder pain according to NRS (numeric rating scale 0-10) 24 hours after the 1st intervention.

    Time frame: 24 hours

  9. Pain measurements on a NRS (Numeric Rating Scale)

    Patients are asked to rate the intensity of their shoulder pain (if any) according to NRS (Numeric rating scale) from 0-10 (0=no pain, 10=the worst pain imaginable). For patients receiving the intervention they are asked to rate the intensity of their pain +2, +5, +10 and +60 minutes after the 1st intervention and +2, +5, +10 and +15 after the 2nd intervention.

    Time frame: 2 hours

06

Study locations

1 of 1 sites recruiting
  • Rigshospitalet
    Copenhagen, 2200, Denmark
    • Eske mr Aasvang, Md, PhD · Contact · eske.aas@gmail.com · 0045 26232076
    • Søren mr Bøgevig, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT02903719
Lead sponsor
Eske Kvanner Aasvang
Responsible party
Eske Kvanner Aasvang (MD, PhD, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Sep 16, 2016
Start date
Sep 2016
Primary completion
Apr 2017 (estimated)
Completion
Apr 2017 (estimated)
Last update
Sep 23, 2016

Study contacts

Søren Mr Bøgevig, MD
Contact
soeren.boegevig.03@regionh.dk
0045 20 66 40 51
Eske mr Aasvang, MD, PhD
Contact
eske.aas@gmail.com
0045 26 23 20 76

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion